vs
Side-by-side financial comparison of ACV Auctions Inc. (ACVA) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $183.6M, roughly 1.5× ACV Auctions Inc.). On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 15.1%). ACV Auctions Inc. produced more free cash flow last quarter ($-14.7M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 12.3%).
ACV Auctions Inc.ACVAEarnings & Financial Report
ACV Auctions Inc. operates a leading digital wholesale vehicle auction platform serving automotive dealers across the U.S. and Canada. It offers end-to-end services including transparent vehicle inspections, secure payment processing, and logistics support, enabling efficient trading of used vehicles between registered wholesale buyers and sellers.
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
ACVA vs GH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.6M | $281.3M |
| Net Profit | — | $-128.5M |
| Gross Margin | — | 64.6% |
| Operating Margin | -9.7% | -43.0% |
| Net Margin | — | -45.7% |
| Revenue YoY | 15.1% | 39.4% |
| Net Profit YoY | — | -15.8% |
| EPS (diluted) | $-0.12 | $-1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.6M | $281.3M | ||
| Q3 25 | $199.6M | $265.2M | ||
| Q2 25 | $193.7M | $232.1M | ||
| Q1 25 | $182.7M | $203.5M | ||
| Q4 24 | $159.5M | $201.8M | ||
| Q3 24 | $171.3M | $191.5M | ||
| Q2 24 | $160.6M | $177.2M | ||
| Q1 24 | $145.7M | $168.5M |
| Q4 25 | — | $-128.5M | ||
| Q3 25 | $-24.5M | $-92.7M | ||
| Q2 25 | $-7.3M | $-99.9M | ||
| Q1 25 | $-14.8M | $-95.2M | ||
| Q4 24 | — | $-111.0M | ||
| Q3 24 | $-16.0M | $-107.8M | ||
| Q2 24 | $-17.1M | $-102.6M | ||
| Q1 24 | $-20.5M | $-115.0M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | 64.7% | ||
| Q2 25 | — | 65.0% | ||
| Q1 25 | — | 63.3% | ||
| Q4 24 | — | 61.6% | ||
| Q3 24 | — | 61.1% | ||
| Q2 24 | — | 59.1% | ||
| Q1 24 | — | 61.2% |
| Q4 25 | -9.7% | -43.0% | ||
| Q3 25 | -11.9% | -37.3% | ||
| Q2 25 | -3.7% | -45.9% | ||
| Q1 25 | -7.9% | -54.6% | ||
| Q4 24 | -16.2% | -62.4% | ||
| Q3 24 | -10.0% | -61.3% | ||
| Q2 24 | -11.6% | -56.8% | ||
| Q1 24 | -15.5% | -59.2% |
| Q4 25 | — | -45.7% | ||
| Q3 25 | -12.3% | -35.0% | ||
| Q2 25 | -3.8% | -43.0% | ||
| Q1 25 | -8.1% | -46.8% | ||
| Q4 24 | — | -55.0% | ||
| Q3 24 | -9.4% | -56.3% | ||
| Q2 24 | -10.6% | -57.9% | ||
| Q1 24 | -14.1% | -68.2% |
| Q4 25 | $-0.12 | $-1.01 | ||
| Q3 25 | $-0.14 | $-0.74 | ||
| Q2 25 | $-0.04 | $-0.80 | ||
| Q1 25 | $-0.09 | $-0.77 | ||
| Q4 24 | $-0.15 | $-0.90 | ||
| Q3 24 | $-0.10 | $-0.88 | ||
| Q2 24 | $-0.10 | $-0.84 | ||
| Q1 24 | $-0.13 | $-0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $271.5M | $378.2M |
| Total DebtLower is stronger | — | $1.5B |
| Stockholders' EquityBook value | $429.7M | $-99.3M |
| Total Assets | $1.1B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $271.5M | $378.2M | ||
| Q3 25 | $265.3M | $580.0M | ||
| Q2 25 | $258.4M | $629.1M | ||
| Q1 25 | $291.9M | $698.6M | ||
| Q4 24 | $224.1M | $525.5M | ||
| Q3 24 | $252.5M | $585.0M | ||
| Q2 24 | $215.0M | $933.7M | ||
| Q1 24 | $209.8M | $1.0B |
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $429.7M | $-99.3M | ||
| Q3 25 | $434.4M | $-354.5M | ||
| Q2 25 | $448.8M | $-305.5M | ||
| Q1 25 | $439.6M | $-250.8M | ||
| Q4 24 | $440.0M | $-139.6M | ||
| Q3 24 | $456.2M | $-60.1M | ||
| Q2 24 | $457.6M | $-1.6M | ||
| Q1 24 | $458.3M | $68.3M |
| Q4 25 | $1.1B | $2.0B | ||
| Q3 25 | $1.2B | $1.3B | ||
| Q2 25 | $1.1B | $1.3B | ||
| Q1 25 | $1.2B | $1.3B | ||
| Q4 24 | $984.1M | $1.5B | ||
| Q3 24 | $1.0B | $1.5B | ||
| Q2 24 | $1.0B | $1.6B | ||
| Q1 24 | $1.0B | $1.7B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-12.4M | $-26.4M |
| Free Cash FlowOCF − Capex | $-14.7M | $-54.2M |
| FCF MarginFCF / Revenue | -8.0% | -19.3% |
| Capex IntensityCapex / Revenue | 1.2% | 9.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $69.1M | $-233.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-12.4M | $-26.4M | ||
| Q3 25 | $10.3M | $-35.4M | ||
| Q2 25 | $13.7M | $-60.3M | ||
| Q1 25 | $66.6M | $-62.7M | ||
| Q4 24 | $-3.2M | $-64.5M | ||
| Q3 24 | $21.1M | $-51.1M | ||
| Q2 24 | $4.5M | $-94.0M | ||
| Q1 24 | $43.0M | $-30.3M |
| Q4 25 | $-14.7M | $-54.2M | ||
| Q3 25 | $7.7M | $-45.8M | ||
| Q2 25 | $10.9M | $-65.9M | ||
| Q1 25 | $65.3M | $-67.1M | ||
| Q4 24 | $-3.9M | $-83.4M | ||
| Q3 24 | $20.2M | $-55.3M | ||
| Q2 24 | $2.7M | $-99.1M | ||
| Q1 24 | $41.9M | $-37.2M |
| Q4 25 | -8.0% | -19.3% | ||
| Q3 25 | 3.8% | -17.3% | ||
| Q2 25 | 5.6% | -28.4% | ||
| Q1 25 | 35.7% | -33.0% | ||
| Q4 24 | -2.5% | -41.3% | ||
| Q3 24 | 11.8% | -28.9% | ||
| Q2 24 | 1.7% | -55.9% | ||
| Q1 24 | 28.8% | -22.1% |
| Q4 25 | 1.2% | 9.9% | ||
| Q3 25 | 1.3% | 3.9% | ||
| Q2 25 | 1.5% | 2.4% | ||
| Q1 25 | 0.7% | 2.2% | ||
| Q4 24 | 0.4% | 9.4% | ||
| Q3 24 | 0.6% | 2.2% | ||
| Q2 24 | 1.1% | 2.9% | ||
| Q1 24 | 0.7% | 4.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACVA
| Auction Marketplace Revenue | $77.6M | 42% |
| Other Marketplace Revenue | $72.4M | 39% |
| Customer Assurance | $24.1M | 13% |
| Data Services Revenue | $9.4M | 5% |
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
